Dermatitis News

Patients who experienced significant elimination of signs and symptoms of rosacea reported a dramatic positive improvement in their lives, according to a survey of 1,044 patients conducted by the National Rosacea Society.

In adults with atopic dermatitis, treatment with cyclosporine or methotrexate appears to have a lower rate of serious infections than mycophenolate, azathioprine and systemic prednisone, according to a study.

In a paper recently published in Journal of the American Academy of Dermatology, researchers proposed there is a three-part pathogenesis of acute inflammatory edema, a form of pseudocellulitis commonly seen in critically ill patients.

Researchers found favorable results in children with vitiligo and in lesions on the face and neck with topical calcineurin inhibitors in a meta-analysis from 46 studies, in the top Healio Dermatology story from last week.

Biological drugs have a small to moderate effect in reducing fatigue in patients with psoriasis vulgaris, but research is needed to understand the underlying causes in this relationship.

Black and Hispanic children had a 1.5-fold and 3.4-fold greater chance, respectively, to be absent at least 6 days from school during a 6-month period because of atopic dermatitis vs. white children, after controlling for sociodemographic factors, according to findings in a cross-sectional study.

Dupilumab decreased the risk for serious or severe infection and nonherpetic skin infections in patients with moderate to severe atopic dermatitis compared with placebo, according to results published in the American Journal of Clinical Dermatology.

Patients with moderate-to-severe psoriasis who failed treatment with an IL-17A agent, had significant disease improvement with brodalumab, according to Grace Kimmel, MD, of the Icahn School of Medicine at Mount Sinai, and colleagues.

CLEVELAND — Patients with rosacea, livedoid vasculopathy and allergic contact dermatitis present with a multitude of dermatologic symptoms that rheumatologists can easily misdiagnose as rheumatic diseases, according to Anthony Fernandez, MD, PhD, of the Cleveland Clinic.

Pfizer announced phase 3 study results from its investigational oral JAK1 inhibitor, abrocitinib, for treating patients aged at least 12 years with moderate to severe atopic dermatitis.